Akebia Therapeutics (AKBA) said Thursday that its Vafseo drug for anemia related to chronic kidney disease has been granted Transitional Drug Add-On Payment Adjustment, or TDAPA, reimbursement, effective Jan. 1, 2025, by the Centers for Medicare and Medicaid Services.
Vafseo is expected to be available in the market in January, according to Akebia. It was approved by the US Food and Drug Administration in March to treat anemia caused by chronic kidney disease in adults.
The TDAPA program provides reimbursement for Vafseo for the next two years on top of the bundled rate under the End-Stage Renal Disease prospective payment system, Akebia said.
The company also said it received a Level II Healthcare Common Procedure Coding System code for Vafseo that will be used by dialysis organizations for billing for Medicare enrollees.
Price: 1.3000, Change: +0.02, Percent Change: +1.56
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。